The Swedish-British company AstraZeneca has suspended the last, third phase of clinical trials of the AZD1222 Oxford vaccine, one of the most promising drugs against coronavirus.
According to Gadin.Net, an employee of the medical journal STAT wrote about it on Twitter.
According to him, one of the volunteers in Britain had a serious reaction.
"This is a simple procedure used to detect a disease whose potential cause is unknown," the company said.
AstraZeneca has not yet determined the nature of the reaction. It is unknown how long the vaccination break will last.
The clinical phase of the vaccination was attended by 20,000 people from different countries. It is noted that 30,000 people will join from the United States.